Trials / Terminated
TerminatedNCT02965846
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are twofold •To evaluate the safety and efficacy of 0.1% AGN-195263 administered twice daily compared to its vehicle in patients with evaporative dry eye (EDE) •To evaluate the systemic pharmacokinetics of 0.1% AGN-195263 administered twice daily in patients with EDE
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-195263 | 1 drop of AGN-195263 will be instilled in each eye twice daily. |
| DRUG | Vehicle | 1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily. |
Timeline
- Start date
- 2016-12-13
- Primary completion
- 2017-06-13
- Completion
- 2017-06-13
- First posted
- 2016-11-17
- Last updated
- 2018-11-30
- Results posted
- 2018-11-30
Locations
49 sites across 12 countries: United States, Czechia, France, Germany, Hungary, Italy, Philippines, Poland, Spain, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02965846. Inclusion in this directory is not an endorsement.